NCT03328078Phase 1, phase 2Recruiting

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Study sponsor: Curis, Inc. · CRIS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-07Estimated
Enrollment · participants152Estimated
Source updated2026-10-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.